Latent Tuberculosis Infection in Cancer Patients
1. To evaluate the performance of the new T-SPOT.TB test and the conventional TST for screening of Latent Tuberculosis infections in patients with cancer and those undergoing Hematopoietic Stem Cell Transplant.
- To examine the factors associated with positive response to T-SPOT.TB and the TST (tuberculin skin test) in patients with anergy.
- To determine the impact of immunosuppressive and antineoplastic therapy on the screening performance of T-SPOT.TB and the TST in cancer patients.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Latent Mycobacterium Tuberculosis Infection Among Cancer Patients|
- Rate of Positive Results of T-SPOT.TB (%) [ Time Frame: Study period 2 Years ] [ Designated as safety issue: No ]Number participants with postitive T-SPOT.TB test results compared to total positive results, derived from Center for Disease Control (CDC) Criteria used for LTBI positive skin test (i.e. a tuberculin skin test (TST) with 5 mm or more of induration). For those individuals with >5 mm induration on TST, chest radiograph performed. Fisher's exact test used to assess the association between categorical variables and the testing results of T-SPOT.TB or TST.
Biospecimen Retention: Samples With DNA
A blood sample will be collected and used to perform the T-SPOT. TB test.
|Study Start Date:||June 2007|
|Study Completion Date:||May 2011|
|Primary Completion Date:||May 2011 (Final data collection date for primary outcome measure)|
Latent Tuberculosis Infection
Patients with cancer at risk for developing active tuberculosis (TB).
Other: T-SPOT TB test
Extra blood draw, followed by ten minutes rest and the injection of Tuberculin subcutaneously on forearm.
Show Detailed Description
|United States, Texas|
|UT MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Amar Safdar, MD||M.D. Anderson Cancer Center|